LAPFS25 - Hot Topics in Myeloma

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Recent developments in multiple myeloma include the FDA approval of linvoseltamab, a bispecific antibody targeting BCMA with a 70% response rate in heavily pretreated patients. Ongoing debate surrounds belantamab mafodotin, an antibody-drug conjugate with promising efficacy but notable ocular toxicity, currently under FDA review despite approval abroad. Minimal residual disease (MRD) testing is gaining prominence as a decision-making tool, with trials like MIDAS evaluating MRD status to guide treatment intensity. Long-term follow-up from the CARTITUDE-1 trial revealed that one-third of patients receiving cilta-cel remained disease-free at five years, raising critical discussions on how to define cure in multiple myeloma. Collectively, these developments highlight significant progress toward durable remission and potential pathways to cure.

View the Slides: https://www.myeloma.org/videos/imf-patient-family-seminar-2025-los-angeles-ca

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
X/Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
LinkedIn: https://www.linkedin.com/company/international-myeloma-foundation

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/523296/#!/donation/checkout?c_src=youtube

Category
Nonprofits & Activism
License
Standard YouTube License

The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.
Categoria
Oncology
Commenta per primo questo video.

Prossimo